


Amendments to the Claims

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims

1-6. Cancelled

7. (Currently amended) A method of treating a bacterial infection in a host comprising the step of administering to the host an effective amount of at least one compound of the formula



wherein R¹ represents

alkanoyl of C₂-C₁₀ which is unsubstituted, or which is substituted by a phenyl, or which is substituted on other than the ~~a-carbon alpha-carbon~~ atom by an amino or protected amino group; benzoyl or substituted benzoyl bearing one or two substituents each of which is independently halo, lower alkyl of C₁-C₄, lower alkoxy of C₁-C₄ or phenyl;

an acyl derived from an ~~a-amino alpha-amino~~ acid or an acyl derived from a protected ~~a-amino alpha-amino~~ acid, said ~~a-amino alpha-amino~~ acid being selected from the group consisting of:


alanine,

arginine,
asparagine,
aspartic acid,
cysteine,
glutamic acid,
glutamine,
glycine,
histidine,
isoleucine,
leucine,
lysine,
methionine,
3-phenylalanine,
3-(p-chlorophenyl)alanine,
proline,
serine,
threonine,
tryptophan and
valine,

in either D- or L-form; or

an acyl derived from an α -amino alpha-amino acid as defined above which bears on the amine a substituent which is alkyl of C₁-C₁₀, benzyl, phenylbenzyl, or p-chlorobenzyl, with the proviso that the acyl derived from N-methyl-D-leucine is excluded;

R² represents hydrogen or an epivancosaminyl of the formula



wherein R^{2a} represents hydrogen or -CH₂- R³ and R³ represents

hydrogen,
alkyl of C₁-C₁₁,
alkyl of C₁-C₁₁-R⁴, or
R⁴-(linker_(0 or 1)-R⁴)_{0 or 1},
wherein each R⁴ is independently phenyl or phenyl substituted by one or two substituents, each of which is independently halo, lower alkyl of C₁-C₈, lower alkoxy of C₁-C₈, lower alkylthio of C₁-C₄, or trifluoromethyl, and "linker" is [-O-] -O-, -CH₂-, or -O- (CH₂)_n- wherein n is 1-3.

8. (Original) A method of Claim 7 wherein the bacterial infection is attributable to a vancomycin-resistant enterococcus.

9-11. Cancelled

12. (Previously presented) The method of Claim 7, wherein R² is an epivancosaminyl radical wherein R^{2a} represents hydrogen.

13. (Previously presented) The method of Claim 12, wherein R² is an epivancosaminyl radical wherein R^{2a} represents -CH₂-R₃.

14. (Previously presented) The method of Claim 13, wherein R³ is p-biphenylyl.

15. (Previously presented) The method of Claim 13, wherein R³ is p-(chlorophenyl) phenyl.